Efficacy of Baricitinib in Moderate Alopecia Areata, Severe Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Real-world Comparative Study.
Description
This dataset supports the findings in the manuscript "Efficacy of Baricitinib in Moderate Alopecia Areata, Severe Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Real-world Comparative Study." The dataset includes:Demographic and baseline characteristics of 95 patients with Alopecia Areata (AA), Alopecia Totalis (AT) and Alopecia Universalis (AU), including age, gender, disease duration, age of onset, number of initial onsets, number of recurrences, and presence of nail lesions.Dermoscopic data including terminal hair density at baseline, 4, 8, 16, and 24 weeks following treatment with baricitinib, for moderate AA, severe AA, AT and AU patient groups.Adverse events data including type and incidence of mild adverse reactions (upper respiratory tract infection, folliculitis, acne, elevated aminotransferase and creatine phosphokinase levels, and local scalp pruritus) during baricitinib treatment.Statistical analysis comparing the effectiveness of baricitinib across the four groups, including p-values for comparisons of terminal hair density.This data provides valuable insights into the real-world effectiveness of baricitinib in treating different subtypes of alopecia areata and highlights the role of dermoscopy in monitoring treatment response. The dataset can be used to validate our findings and for further research on alopecia areata and the use of JAK inhibitors.